Disc Medicine (IRON)
Develops heme and iron-homeostasis therapies for serious blood disorders.
$65.58
vs last close−2.90 (−4.23%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19 | 30 | 31 | 31 | 33 | 35 | 40 | 61 | 68 | 67 | 70 | 65 | |
| Research & development | 14 | 23 | 24 | 23 | 25 | 25 | 28 | 46 | 50 | 46 | 46 | 47 |
| 5 | 7 | 8 | 7 | 8 | 10 | 12 | 15 | 17 | 21 | 24 | 18 | |
| General & administrative | 5 | 7 | 8 | 7 | 8 | 10 | 12 | 15 | 17 | 21 | 24 | 18 |
| Operating income | −19 | −30 | −31 | −31 | −33 | −35 | −40 | −61 | −68 | −67 | −70 | −65 |
| 5 | 6 | 5 | 5 | 6 | 5 | 6 | 6 | 5 | 7 | 6 | 6 | |
| Interest income | 5 | 5 | 5 | 5 | 6 | 6 | 7 | 7 | 6 | 7 | 7 | 7 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Other non-operating income | 0 | −6 | −5 | −5 | −6 | −21 | −7 | −7 | −6 | −7 | −7 | −7 |
| Income before tax | −14 | −24 | −27 | −26 | −26 | −29 | −34 | −55 | −62 | −60 | −63 | −59 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −14 | −24 | −27 | −26 | −27 | −29 | −34 | −55 | −62 | −61 | −64 | −60 |
| Net income | −14 | −24 | −27 | −26 | −27 | −29 | −34 | −55 | −62 | −61 | −64 | −60 |
| EPS, basic | −$0.58 | −$1.00 | −$1.09 | −$1.03 | −$0.89 | −$0.98 | −$1.02 | −$1.58 | −$1.77 | −$1.64 | −$1.65 | −$1.54 |
| EPS, diluted | −$0.58 | −$1.00 | −$1.09 | −$1.03 | −$0.89 | −$0.98 | −$1.02 | −$1.58 | −$1.77 | −$1.64 | −$1.65 | −$1.54 |
| Weighted average shares, basic | 24 | 24 | 25 | 26 | 30 | 30 | 33 | 35 | 35 | 35 | 38 | 39 |
| Weighted average shares, diluted | 24 | 24 | 25 | 26 | 30 | 30 | 33 | 35 | 35 | 35 | 38 | 39 |
| EBITDA | −19 | −24 | −27 | −26 | −26 | −13 | −33 | −54 | −61 | −59 | −63 | −58 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −19 | −24 | −27 | −26 | −26 | −13 | −33 | −54 | −61 | −60 | −63 | −59 |
